Rare Disease Report
Physicians
Physicians
Patients & Caregivers

TFPI, anti-TFPI, and Hemophilia

FEBRUARY 15, 2016
Jen Schroeder, MD, PhD



In this interview with Rare Disease Report during the 57th ASH Annual Meeting, Jen Schroeder, MD, PhD, of Bayer talks about the preclinical studies presented at the ASH meeting that has compelled the company to begin a phase 1 study with anti-tissue factor pathway inhibitor (anti-TFPI) antibody BAY-1093884 for the treatment of hemophilia A.

References

  • Xu V, Koellenberger M, Laux V, Kauser K, Sim D.  Acute Efficacy of a Novel Anti-Tissue Factor Pathway Inhibitor Antibody BAY 1093884 in Hemophilia A Mouse Severe Tail Bleeding. Poster presented at 57th Annual Meeting; Orlando, Florida; December 4-8, 2015. Abstract 3500.
  • Paz P, Xie J, Aswad F. Antibody Engineering of Anti-TFPI Bypass Therapeutic BAY 1093884: Isotype Selection and Sequence Optimization. Poster presented at 57th Annual Meeting; Orlando, Florida; December 4-8, 2015. Abstract 3496.
  • Bauzon M, Grudzinska-Goebel J, Tebbe J, et al. Characterization of a High-Affinity Fully Human IgG2 Antibody Against Tissue Factor Pathway Inhibitor As a Bypass Agent for the Treatment of Hemophilia. Poster presented at 57th Annual Meeting; Orlando, Florida; December 4-8, 2015. Abstract 3513.


Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.